CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,484 enrolled
Drug / intervention
Bosutinib +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05286528
NCT05286528N/ACompleted

Retrospective, Non-interventional Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

Pfizer·observational·Posted Mar 18, 2022·Updated Oct 27, 2023

In Brief

An observational study evaluating Bosutinib, Imatinib, and 3 other interventions for Chronic Myeloid Leukaemia. Completed, enrolled 1,484 participants across 1 site.

Detailed Summary

The objectives of this study are to describe patient demographics, clinical and disease characteristics and treatment patterns of Chronic Lymphoid Leukaemia (CML) in Hungary. The primary endpoint of this study is the overall survival of CML patients treated with tyrosine kinase inhibitors in Hungary. The Overall Survival (OS) of all enrolled patients, OS by sequence pattern and by the number of treatment lines will be analyzed. Secondary objectives are description of the treatment length in 1st and later lines, incidence and prevalence of CML, the patient demographics (as age, gender, comorbidities), average number of patients' comorbidities, most frequent comorbidities and patient number with comorbidities at baseline and at different treatment lines by investigated Thyrosine Kinase Inhibitor (TKI), distribution of the investigated TKI therapies by treatment lines

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesHungary
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedMar 18, 2022
Enrollment StartNov 18, 2020
Primary CompletionJan 31, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 4.3 years ago

Interventions

Bosutinibdrug

Bosutinib as prescribed in real world

Imatinibdrug

Imatinib as prescribed in real world

Nilotinibdrug

Nilotinib as prescribed in real world

Dasatinibdrug

Dasatinib as prescribed in real world

Ponatinibdrug

Ponatinib as prescribed in real world